GRI stock icon



About: GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Employees: 4

Funds holding %
of 6,702 funds
Analysts bullish %
News positive %
of 8 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

114% more capital invested

Capital invested by funds: $82.8K [Q4 2023] → $177K (+$94.4K) [Q1 2024]

19.1% more ownership

Funds ownership: 4.81% [Q4 2023] → 23.9% (+19.1%) [Q1 2024]

33% less funds holding

Funds holding: 9 [Q4 2023] → 6 (-3) [Q1 2024]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for GRI.

Financial journalist opinion

Based on 8 articles about GRI published over the past 30 days